logo BDSP

Base documentaire

  1. Nucleic acid immunization : a prophylactic gene therapy ?

    Article, Communication - En anglais

    WHO meeting on nucleic acid vaccines. Geneva CHE, 1994/05/17.

    Nucleic acid (NA) vaccines may offer the safety of subunit or inactivated vaccines and, at the same time, provide the advantages of live recombinant vaccines, such as induction of a protective cellular immune response.

    In Germany, te so-called « Gene Law » regulates the genetic modification of organisms such as prokaryotic or eukaryotic cells for the construction of recombinant NAs intended for use as NA vaccines.

    Neither NAs nor human beings treated with NAs are subject to Gene Law regulations but preclinical laboratory experiments are regulated by the Gene Law.

    Mots-clés Pascal : Thérapie génique, Réglementation, Allemagne, Immunisation, Sécurité, Essai préclinique, SIDA, Europe, Virose, Infection, Vaccin, Acide nucléique

    Mots-clés Pascal anglais : Gene therapy, Regulation, Germany, Immunization, Safety, Preclinical trial, AIDS, Europe, Viral disease, Infection, Vaccine, Nucleic acid

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0086587

    Code Inist : 002A31D01C2. Création : 09/06/1995.